Experts warn of health dangers as unregulated peptide market booms
Dermatologists caution that popular peptides like Melanotan II carry serious side effects, while a push to reclassify them could legitimize risky gray-market products.
Social-media influencers have popularized a range of synthetic peptides, with Melanotan II—dubbed the “Barbie peptide”—promoted for a sun-free tan, appetite suppression, and libido boost. Dermatologists Dr. Sungat Grewal and Dr. Caren Campbell explain that the peptide stimulates multiple melanocortin receptors, leading to side effects such as atypical moles, priapism, hypertension, and even rhabdomyolysis. Because most of these products are sold under a “research-use only” label, users receive no guarantee of sterility or correct dosage.
Advocates like Robert F. Kennedy Jr. argue that reclassifying certain peptides would let regulated compounding pharmacies supply them, reducing contamination risks. However, an FDA advisory panel’s recommendation to reclassify six of seven peptides conflicted with FDA staff’s opposition, and the agency’s final ruling could take up to a year. Meanwhile, the peptide market continues to thrive, with clinics in Los Angeles and mobile IV services offering Melanotan II for as little as $95.
Why it matters
Unregulated peptide use poses health risks, and pending regulatory changes could expand access to potentially unsafe drugs.
In this story
